Number

ID

Age (years)

Tsize (mm)

Lymph node status

Grade

UICC stage

ER

PR

HER2/neu

Subtype


1

52

49

23

Negative

1

2A

P

P

N

Luminal A

2

53

52

30

Negative

3

2A

N

N

P

Her2 overexpressing

3

54

57

45

Negative

3

2A

N

N

P

Her2 overexpressing

4

56

51

21

Negative

3

2A

P

P

N

Luminal A

5

58

68

15

Negative

3

1

P

N

N

Luminal A

6

59

42

22

Negative

3

2A

N

N

N

Triple negative

7

60

54

26

Negative

3

2A

N

P

N

Luminal A

8

61

35

22

Negative

3

2A

P

P

N

Luminal A

9

62

50

16

Negative

3

1

N

N

N

Triple negative

10

63

49

25

Negative

2

2A

N

N

N

Triple negative

11

64

59

20

Negative

3

1

N

P

N

Luminal A

12

65

58

22

Negative

3

2A

P

P

N

Luminal A

13

66

58

18

Negative

1

1

N

P

P

Her2 overexpressing

14

67

66

22

Negative

3

2A

P

P

N

Luminal A

15

94

56

17

Negative

1

1

N

N

N

Triple negative

16

95

48

30

Negative

3

2A

N

N

P

Her2 overexpressing

17

96

60

26

Negative

3

2A

P

P

N

Luminal A

18

97

56

29

Negative

2

2A

P

P

N

Luminal A

19

98

50

3

Negative

2

1

P

P

N

Luminal A

20

99

40

7

Negative

1

1

P

P

N

Luminal A

21

100

40

6

Negative

2

1

P

P

N

Luminal A

22

101

58

35

Negative

2

2A

P

P

N

Luminal A

23

102

64

34

Negative

3

2A

P

P

N

Luminal A

24

103

66

26

Negative

1

2A

P

P

N

Luminal A

25

104

84

16

Negative

2

1

N

P

N

Luminal A

26

105

57

7

Negative

3

1

N

P

N

Luminal A

27

106

68

35

Negative

3

2A

P

P

N

Luminal A

28

107

40

20

Negative

2

1

P

P

P

Luminal B

29

108

49

35

Negative

3

2A

N

N

N

Triple negative

 ER, oestrogen receptor; HER2/neu, verbb2 erythroblastic leukaemia viral oncogene homolog 2 receptors; ID, identification; N, negative confirmed; PR, progesterone receptor; P, positive confirmed; Tsize, Tumour size in mm; UICC, stage of breast tumour according to the international union against cancer staging criteria.